BrightGene Bio-Medical Technology Management
Management criteria checks 3/4
BrightGene Bio-Medical Technology's CEO is Jiandong Yuan, appointed in Jan 2021, has a tenure of 3.92 years. directly owns 32.24% of the company’s shares, worth CN¥4.10B. The average tenure of the management team and the board of directors is 6.6 years and 4.3 years respectively.
Key information
Jiandong Yuan
Chief executive officer
CN¥1.9m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.9yrs |
| CEO ownership | 32.2% |
| Management average tenure | 6.6yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 28% Price Boost Is Out Of Tune With Earnings
Oct 01
Is BrightGene Bio-Medical Technology (SHSE:688166) Using Too Much Debt?
Sep 19Some BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shareholders Look For Exit As Shares Take 29% Pounding
Aug 01BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up
May 21BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Mar 01CEO
Jiandong Yuan (54 yo)
3.9yrs
Tenure
CN¥1,912,700
Compensation
Mr. Jiandong Yuan serves as the Chairman and General Manager of BrightGene Bio-Medical Technology Co., Ltd. (Formerly known as Borui Biopharmaceutical (Suzhou) Co., Ltd.) since 2021 and is its Director sin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 3.9yrs | CN¥1.91m | 32.24% CN¥ 4.1b | |
| Chief Financial Officer | 9.3yrs | CN¥436.60k | no data | |
| Board Secretary | 3.3yrs | CN¥441.50k | no data | |
| Deputy General Manager | 9.3yrs | CN¥974.60k | no data | |
| Accounting Supervisor | no data | no data | no data |
6.6yrs
Average Tenure
50.5yo
Average Age
Experienced Management: 688166's management team is seasoned and experienced (6.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 9.3yrs | CN¥1.91m | 32.24% CN¥ 4.1b | |
| Director | 3.3yrs | no data | no data | |
| Chairman of the Supervisory Board | 4.6yrs | no data | no data | |
| Supervisor | 7.3yrs | no data | no data | |
| Supervisor | 3.3yrs | no data | no data | |
| Employee Representative Supervisor | 4.3yrs | no data | no data | |
| Employee Representative Supervisor | 3.3yrs | no data | no data |
4.3yrs
Average Tenure
39yo
Average Age
Experienced Board: 688166's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 07:50 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BrightGene Bio-Medical Technology Co., Ltd. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yue Gao | Changjiang Securities Co. LTD. |
| Shitong Han | Citic Securities Co., Ltd. |
| Yu Wu | CMB International Securities Limited |